| Dr Margaret So He Lee, MD, PHD | |
|
300 Longwood Ave, Fegan 6, Boston, MA 02115-5724 | |
| (617) 355-6117 | |
| (617) 730-0308 |
| Full Name | Dr Margaret So He Lee |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Location | 300 Longwood Ave, Boston, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518120674 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207NP0225X | Dermatology - Pediatric Dermatology | 222271 (Massachusetts) | Secondary |
| 207N00000X | Dermatology | 222271 (Massachusetts) | Primary |
| Entity Name | Massachusetts Institute Of Technology |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346308723 PECOS PAC ID: 5597658666 Enrollment ID: O20040203000789 |
News Archive
A.C.T. Holdings and Advanced Cell Technology, Inc. (ACT) reported the first derivation of human embryonic stem cells in completely feeder-layer-free and serum-free conditions.
A team led by Johns Hopkins Children's Center scientists has identified and successfully tamed an overactive protein that plays a key role in cystic fibrosis (CF), a genetic disorder that interferes with the body's ability to transport chloride in and out of cells.
Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today the closing of a CHF25 million (USD26 million) extension to its Series C financing. Investors in the Series C round, including Eclosion, Edmond de Rothschild Investment Partners, Vesalius Biocapital Partners, MP Healthcare Venture, all participated in the financing extension.
NanoViricides, Inc. reports that its anti-HIV drug candidates demonstrated efficacy in the recently completed cell culture studies using two distinctly different HIV-1 isolates. The studies were performed in the laboratory of Carol Lackman-Smith at the Southern Research Institute, Frederick, Maryland.
› Verified 4 days ago
| Entity Name | Boston University Dermatology Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376532853 PECOS PAC ID: 7012803919 Enrollment ID: O20040226000806 |
News Archive
A.C.T. Holdings and Advanced Cell Technology, Inc. (ACT) reported the first derivation of human embryonic stem cells in completely feeder-layer-free and serum-free conditions.
A team led by Johns Hopkins Children's Center scientists has identified and successfully tamed an overactive protein that plays a key role in cystic fibrosis (CF), a genetic disorder that interferes with the body's ability to transport chloride in and out of cells.
Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today the closing of a CHF25 million (USD26 million) extension to its Series C financing. Investors in the Series C round, including Eclosion, Edmond de Rothschild Investment Partners, Vesalius Biocapital Partners, MP Healthcare Venture, all participated in the financing extension.
NanoViricides, Inc. reports that its anti-HIV drug candidates demonstrated efficacy in the recently completed cell culture studies using two distinctly different HIV-1 isolates. The studies were performed in the laboratory of Carol Lackman-Smith at the Southern Research Institute, Frederick, Maryland.
› Verified 4 days ago
| Entity Name | Internal Medical Associates-ebnhc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558481879 PECOS PAC ID: 6103814371 Enrollment ID: O20040505000853 |
News Archive
A.C.T. Holdings and Advanced Cell Technology, Inc. (ACT) reported the first derivation of human embryonic stem cells in completely feeder-layer-free and serum-free conditions.
A team led by Johns Hopkins Children's Center scientists has identified and successfully tamed an overactive protein that plays a key role in cystic fibrosis (CF), a genetic disorder that interferes with the body's ability to transport chloride in and out of cells.
Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today the closing of a CHF25 million (USD26 million) extension to its Series C financing. Investors in the Series C round, including Eclosion, Edmond de Rothschild Investment Partners, Vesalius Biocapital Partners, MP Healthcare Venture, all participated in the financing extension.
NanoViricides, Inc. reports that its anti-HIV drug candidates demonstrated efficacy in the recently completed cell culture studies using two distinctly different HIV-1 isolates. The studies were performed in the laboratory of Carol Lackman-Smith at the Southern Research Institute, Frederick, Maryland.
› Verified 4 days ago
| Entity Name | East Boston Neighborhood Health Center Corp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316994411 PECOS PAC ID: 9032356050 Enrollment ID: O20130513000045 |
News Archive
A.C.T. Holdings and Advanced Cell Technology, Inc. (ACT) reported the first derivation of human embryonic stem cells in completely feeder-layer-free and serum-free conditions.
A team led by Johns Hopkins Children's Center scientists has identified and successfully tamed an overactive protein that plays a key role in cystic fibrosis (CF), a genetic disorder that interferes with the body's ability to transport chloride in and out of cells.
Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today the closing of a CHF25 million (USD26 million) extension to its Series C financing. Investors in the Series C round, including Eclosion, Edmond de Rothschild Investment Partners, Vesalius Biocapital Partners, MP Healthcare Venture, all participated in the financing extension.
NanoViricides, Inc. reports that its anti-HIV drug candidates demonstrated efficacy in the recently completed cell culture studies using two distinctly different HIV-1 isolates. The studies were performed in the laboratory of Carol Lackman-Smith at the Southern Research Institute, Frederick, Maryland.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Margaret So He Lee, MD, PHD 300 Longwood Ave, Fegan 6, Boston, MA 02115-5724 Ph: (617) 355-6117 | Dr Margaret So He Lee, MD, PHD 300 Longwood Ave, Fegan 6, Boston, MA 02115-5724 Ph: (617) 355-6117 |
News Archive
A.C.T. Holdings and Advanced Cell Technology, Inc. (ACT) reported the first derivation of human embryonic stem cells in completely feeder-layer-free and serum-free conditions.
A team led by Johns Hopkins Children's Center scientists has identified and successfully tamed an overactive protein that plays a key role in cystic fibrosis (CF), a genetic disorder that interferes with the body's ability to transport chloride in and out of cells.
Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today the closing of a CHF25 million (USD26 million) extension to its Series C financing. Investors in the Series C round, including Eclosion, Edmond de Rothschild Investment Partners, Vesalius Biocapital Partners, MP Healthcare Venture, all participated in the financing extension.
NanoViricides, Inc. reports that its anti-HIV drug candidates demonstrated efficacy in the recently completed cell culture studies using two distinctly different HIV-1 isolates. The studies were performed in the laboratory of Carol Lackman-Smith at the Southern Research Institute, Frederick, Maryland.
› Verified 4 days ago
Erica Dommasch, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 330 Brookline Ave, Shapiro 2, Boston, MA 02215 Phone: 617-667-3753 | |
Dr. Chantal Louise Cotter, MB BCH BAO Dermatology Medicare: Not Enrolled in Medicare Practice Location: 300 Longwood Ave, Boston, MA 02115 Phone: 617-355-6117 | |
Dr. John J Croke, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 725 Albany St, Shapiro 8, Boston, MA 02118 Phone: 617-638-7420 Fax: 617-638-7289 | |
Dr. Debjani Sahni, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 725 Albany Street, Shapiro 8, Boston, MA 02118 Phone: 617-638-7420 Fax: 617-638-7289 | |
Dr. Joseph C Kvedar, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 50 Staniford St, Suite 200, Boston, MA 02114 Phone: 617-726-2914 Fax: 617-724-2135 | |
Ryan Char Kelm, Dermatology Medicare: Medicare Enrolled Practice Location: 50 Staniford St # 250, Boston, MA 02114 Phone: 617-724-6960 | |
Dr. David Attar Hashemi, MD, MBA Dermatology Medicare: Medicare Enrolled Practice Location: 50 Staniford St, Boston, MA 02114 Phone: 617-726-2914 |